Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.
Soft tissue sarcoma (STS) is a rare cancer that develops from soft tissues in any part of the body. Despite major advances in the treatment of STS, patients are often refractory to conventional radiotherapy, leading to poor prognosis. Enhancement of sensitivity to radiotherapy would therefore improv...
Main Authors: | Toshinori Omori, Hiroshi Tazawa, Yasuaki Yamakawa, Shuhei Osaki, Joe Hasei, Kazuhisa Sugiu, Tadashi Komatsubara, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0250643 |
Similar Items
-
Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy
by: Hiroshi Tazawa, et al.
Published: (2020-02-01) -
Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
by: Koji Uotani, et al.
Published: (2024-01-01) -
Multidisciplinary oncolytic virotherapy for gastrointestinal cancer
by: Toshiyoshi Fujiwara
Published: (2019-07-01) -
Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment
by: Shuya Yano, et al.
Published: (2021-01-01) -
Oncolytic virotherapy
by: Daniel Cervantes-García;, et al.
Published: (2008-01-01)